Clinical Trials Logo

Cannabis clinical trials

View clinical trials related to Cannabis.

Filter by:

NCT ID: NCT04810858 Recruiting - HIV Clinical Trials

Modeling the Effects of Chronic Marijuana Use on Neuroinflammation and HIV-related Neuronal Injury

CHI
Start date: August 18, 2021
Phase: N/A
Study type: Interventional

This study applies a hypothesis-driven approach to examine the effects of chronic marijuana use on HIV-associated inflammation and its subsequent impacts on central nervous system function, with the goal of identifying the mechanisms through which cannabinoids modulate neurological disorders and other comorbidities in persons with HIV.

NCT ID: NCT04775030 Recruiting - Clinical trials for Temporomandibular Disorder

Methodology for Developing an Occlusal Appliance With CBD Active Carrier

CBD-OCC-APP
Start date: January 1, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Evaluation of the efficacy of the occlusal appliance with active cannabidiol (CBD) molecules in TMD patients

NCT ID: NCT04741477 Completed - Cannabis Clinical Trials

The Pharmacokinetics and Pharmacodynamics of Hemp-based Topical Cannabinoid Products

Start date: July 14, 2021
Phase: Phase 1
Study type: Interventional

This study will evaluate the pharmacokinetic and pharmacodynamic effects of hemp-based Cannabidiol (CBD) topical products (e.g., lotions, creams, patches) that contain low levels of delta-9-tetrahydrocannabinol (THC).

NCT ID: NCT04704271 Recruiting - Cannabis Clinical Trials

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II

THC-Gender-II
Start date: October 9, 2019
Phase: Phase 1
Study type: Interventional

The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.

NCT ID: NCT04693884 Active, not recruiting - Clinical trials for Cardiovascular Risk Factor

Cannabis Inhalation: Effects on Cardiovascular Function During Rest and Exercise

Start date: September 1, 2021
Phase: Early Phase 1
Study type: Interventional

This two-phase project seeks to examine the cardiovascular response to consumption of cannabis variants of different cannabinoid composition through different methods (smoking vs. vaporizing), at rest and during aerobic exercise. Multiple measures that have been shown to predict risk factors for chronic-disease and negative health outcomes will be assessed following cannabis consumption at rest or in combination with exercise. These techniques will examine arterial stiffness, vascular function, and cardiac function. In phase I and II, subjects will visit the lab on 6 different occasions; with 1 visit acting as an introductory visit, 1 as an exercise control visit, 2 as resting cannabis visits, and 2 as cannabis + exercise visits. Cannabis used in phase I of this study will consist of approximately 10% THC. On all visits, pulse wave velocity, flow mediated dilation, and echocardiography measures will be performed following cannabis consumption by smoking or vaporizing, and cannabis consumption by smoking or vaporizing followed by 20 minutes of exercise on a cycle ergometer. Phase II of the study will implore a similar design. In favor of altering method of consumption, in all visits cannabis will be consumed by vaporization and will be either a high cannabidiol (CBD: (~10%)) and low delta-9-tetrahydrocannabinol (THC: (<1%)), or a high THC (~10%) and low CBD (<1%) variant.

NCT ID: NCT04634136 Completed - Quality of Life Clinical Trials

Full-spectrum Medical Cannabis for Treatment of Spasticity in Patients With Severe Forms of Cerebral Palsy

HemPhar
Start date: October 15, 2020
Phase: N/A
Study type: Interventional

The proposed study is a double-blind, placebo-controlled, cross over study on 60 children aged 5 to 25 years with severe spasticity related to cerebral palsy (CP), level IV and V with full-spectrum medical cannabis product of CBD/THC ratio 10:1.

NCT ID: NCT04601207 Completed - Healthy Clinical Trials

A Study Investigating the Bioavailability of CBD and THC in an Emulsion Product in a Healthy Population

Start date: June 19, 2020
Phase: Phase 1
Study type: Interventional

The objective of this study is to investigate the bioavailability of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) in an emulsion product against a comparator product. Thirty-two participants will be randomized into a single-center, double-blind, parallel trial. Participants will be dosed in clinic and blood and urine samples will be taken over a 12-hour period. Blood and urine samples will also be collected for 48 hours post-dose at check-in visits. Questionnaires regarding drug effects and cognitive function will also be completed following each blood sampling. Participants who consumed the comparator product will be asked to return to the clinic following a wash-out period of at least 45 days to consume the emulsion product in-clinic and complete questionnaires at the same specified time points over a 12-hour period.

NCT ID: NCT04596644 Suspended - Pain Clinical Trials

Impact of Repeatedly-Administered THC-cannabis on Experimental Pain and Abuse Liability in Humans

Start date: August 1, 2021
Phase: Phase 2
Study type: Interventional

Chronic pain is a significant public health concern in the U.S., for which prescription opioids have historically been the standard treatment. This has resulted in striking rates of opioid use disorders and fatal overdoses. Identifying non-opioid medications for the management of chronic pain with minimal abuse liability is a public health necessity, and cannabinoids are a promising drug class for this purpose. More than 80% of medicinal cannabis users report pain as their primary medical indication, and they report experiencing minimal psychoactive effects. However, there are few well-controlled human laboratory studies assessing cannabis' efficacy for pain in the context of abuse, and even less is known regarding the effects of daily repeated use of cannabis on pain and its relationship to abuse liability. Carefully controlled research is needed. The proposed randomized, within-subjects, placebo-controlled 16-day crossover inpatient human laboratory study (N = 20 healthy cannabis users; 10 men, 10 women) will address three important gaps in our understanding of the potential therapeutic utility of cannabis for pain: 1) Does tolerance develop to repeated, daily smoked cannabis administration on measures of experimental pain and abuse liability; 2) If so, is tolerance reversed during the 7 days of abstinence from active-THC cannabis; 3) Does abrupt abstinence from active cannabis increase experimental pain sensitivity, i.e. hyperalgesia, relative to baseline, and do these effects parallel measures of cannabis withdrawal such as disrupted mood and sleep? Two distinct modalities of experimental pain will be assessed: The Cold Pressor Test (CPT) and Quantitative Sensory Testing Thermal Temporal Summation (QST-TTS). Throughout the study, experimental pain and abuse-related effects will be assessed, as will sleep and subjective mood assessments.

NCT ID: NCT04587700 Completed - Cannabis Clinical Trials

Analgesic Consumption in Chronic Marijuana Users Following Orthopedic Trauma Surgery

Start date: September 21, 2020
Phase:
Study type: Observational

Marijuana use has increased since its legalization in Canada and many believe that it may help patients that are experiencing chronic pain. The investigators want to assess if patients who have used marijuana chronically will need more medication to control their pain after they have undergone orthopedic trauma surgery (ex. Hip, femur, humerus fractures etc.). In this study, the investigators will identify chronic marijuana users (ie. those using for 3 months or more) who are undergoing orthopedic trauma surgery to assess how much pain medication they need post-operatively and compare this with non-users. The investigators will also evaluate their pain scores, pain medication use and other complications that they may have during or after their surgeries, including any nausea/vomiting, heart or breathing problems.

NCT ID: NCT04585841 Completed - Cancer Clinical Trials

The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy

Start date: December 1, 2020
Phase: Phase 1
Study type: Interventional

An intervention study on the effect of cannabidiol on lean body mass in cancer patients receiving chemotherapy, at the department of Clinical Oncology at Zealand University Hospital, Roskilde, Denmark. Fat free mass will be measured by bioimpedance spectroscopy. As secondary outcomes protein and energy intake, nausea, taste alterations and life quality will be assessed by oral interviews and questionnaires.